S.91. Changes in the Proinflammatory Cytokine Profile in Human Limbal Epithelial Cells Treated with Dialyzable Leukocyte Extracts

Robles-Contreras, Atzín; Vizuet, Lizet; Rivera, Erika; Lopez-Gonzalez, Jessica; Serafín‐López, Jeanet; Pérez, Mayra; Estrada-Garcia, Iris; Estrada‐Parra, Sergio; Garfias, Yonathan; Jiménez-Martínez, María Carmen

doi:10.1016/j.clim.2009.03.464

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…During 1-9 years follow-up [1]. As result, cell-mediated immune response develops against target antigen [2], and it comprises interleukins (IL-6 and IL-8) produced by activated monocytes [3,4]. Particular factors that decrease cell mediated immunity, Th2 supremacy are age, immunodeficiency, cytotoxic cancer treatments, chronical stress, metastatic diseases, environment, etc.…”

Section: Results -Immunologic and Clinical Responsementioning

confidence: 99%

Transfer Factors or Dialyzable leukocyte Extracts as Immunomodulating Peptides: A Conceptual Review on Broad Spectrum of Therapeutic Areas, Immunologic and Clinical Responses, Trends and Perspectives

Dina¹,

KS²,

Michele³

et al. 2019

Int J Immunol Immunother

View full text Add to dashboard Cite

Immune Modulating Peptides (IMP) discussed in literature as a universal immunocorrectors with wide areas of usage which balance the immune system without causing global immune suppression or overreaction. The present article aim is to review the effect and drawbacks of IMPs in form of Dialyzable leukocyte Extracts (DLE) or Transfer Factors (TF) during and following chemotherapy, radiotherapy, drugs interactions, cancer response and clinical outcomes in different cases of cancers such as metastatic breast cancer, glioma, prostate cancer, osteosarcoma and others. The considered cases of immune overreaction and IMP's impact include autoimmune diseases such as rheumatoid arthritis, multiple sclerosis and allergic reactions. The most difficult therapeutic decision is to choose the right treatment for patients with cancer and autoimmune diseases as they both attempt to supervise and control the immune system, managing immune cells in opposite sides. As patients with autoimmune disease experience difficulty to stay in such treatment when immune cells stimulated in order to identify and destroy cancer cells the IMP as immunocorrectors become one of the main and only healthy choices. The universal mechanism of IMPs action and the absence of contraindications extend the indications for their use in pediatric practice. This includes the complex treatment of respiratory viral infections, the possibility of using in frequently ill children with clinical signs of immune dysfunction and acute intestinal infections. According to the reports on safety, absence of adverse and side effects along with positive outcome for patients the IMPs considered as valuable immunocorrector.

show abstract

Section: Results -Immunologic and Clinical Responsementioning

confidence: 99%

Transfer Factors or Dialyzable leukocyte Extracts as Immunomodulating Peptides: A Conceptual Review on Broad Spectrum of Therapeutic Areas, Immunologic and Clinical Responses, Trends and Perspectives

Dina¹,

KS²,

Michele³

et al. 2019

Int J Immunol Immunother

View full text Add to dashboard Cite

show abstract

“…As a consequence, cell-mediated immune response develops against the target antigen, [8] and it includes interleukins (Il-6 and Il-8) formed by activated monocytes. [22,23] According to Ojeda et al [22], the regulation of the production of TNFa, Il-6 and Il-8 is associated with effects on toll-like receptors (TLR2 and TLR4) expression and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) and cyclic adenosine monophosphate activities. Subsequently, however, the role of the ligands for TLR4 as regulators of the production of these cytokines was excluded.…”

Section: Composition Physicochemical and Biochemical Properties Of Dlementioning

confidence: 99%

Dialysable leukocyte extracts in immunotherapy

Arnaudov

Kostova

2015

Biotechnology & Biotechnological Equipment

View full text Add to dashboard Cite

Dialysable leukocyte extracts (DLE) are complexes consisting of a large number of low-molecular-weight substances. These extracts have immunomodulatory properties, which are mainly attributed to small peptides commonly referred to as 'transfer factor'. This review focuses on the characteristics of DLE with transfer factor activity, together with the methods for their preparation and purification. The opportunities for applying the extracts for immunotherapy purposes against various diseases in humans and domestic animals are also discussed. Their ease of preparation and relatively low cost combined with the rapid positive effect they produce will make DLE subject to application in medicine in the future, including their use against new nosological entities.

show abstract

S.91. Changes in the Proinflammatory Cytokine Profile in Human Limbal Epithelial Cells Treated with Dialyzable Leukocyte Extracts

Cited by 2 publications

References 0 publications

Transfer Factors or Dialyzable leukocyte Extracts as Immunomodulating Peptides: A Conceptual Review on Broad Spectrum of Therapeutic Areas, Immunologic and Clinical Responses, Trends and Perspectives

Transfer Factors or Dialyzable leukocyte Extracts as Immunomodulating Peptides: A Conceptual Review on Broad Spectrum of Therapeutic Areas, Immunologic and Clinical Responses, Trends and Perspectives

Dialysable leukocyte extracts in immunotherapy

Contact Info

Product

Resources

About